The “2025 DIA China Annual Meeting” was successfully held at the Zhangjiang Science Hall in Shanghai from May 22 to 25. The conference was themed “Gathering Global Wisdom to Lead Pharmaceutical Innovation,” bringing together representatives of global drug regulatory agencies, scientific researchers and industry leaders to discuss international collaboration and innovative development in the field of biomedicine.
Professor Hu Yuanjia, director of the Centre for Pharmaceutical Regulatory Sciences (CPRS) at the University of Macau, was invited to participate in the roundtable discussion session “Creating Impact- New Paradigms for Utilization of AI Across the Medical Product Development Continuum.” He discussed with Dr. Cynthia L. VERST, president of Clinical Operations for the Research & Development Solutions organization at IQVIA, Cao Hui, deputy director of the Digital Laboratory of Shanghai Center for Drug Evaluation and Inspection, Sahir ALI, founder and partner of Modi Ventures, and Professor Zhao Liang of the Department of Bioengineering and Therapeutic Sciences in the Schools of Pharmacy and Medicine at the University of California, San Francisco how emerging tools such as artificial intelligence can be better applied in research and development (R&D) of drugs, clinical trials and other fields to improve the speed of R&D, data quality and reliability.
Dr. Li Chihua, assistant professor at the Institute of Chinese Medical Sciences and CPRS, also attended the meeting. He said that participating in this event would help to gain a deeper understanding of the latest developments in drug regulation at home and abroad, promote drug innovation and regulatory modernization, and build high-quality regulatory standards from a global perspective.
As an industry event that brings together international drug regulatory agencies and global clinical study sites and contract research organizations/contract development and manufacturing organizations (CROs/CDMOs), the “2025 DIA China Annual Meeting” focused on multiple interdisciplinary and cutting-edge hot topics such as regulatory science, clinical science, clinical trial operations, AI Pharma, advanced therapy medicinal products (ATMP), pharmacovigilance and drug safety, data science, drug development strategies, and international layout of mature and emerging markets. It connects China with global clinical study sites and international drug regulatory agencies, enhances China’s hard power in the R&D of new drugs, and establishes a global integrated healthy ecological system for industrial development.
Group photo of experts at the roundtable discussion session
Prof. Hu Yuanjia, director of CPRS (middle)